Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Advancing Industrial Chemistry: Exploring the Bioassay and Efficacy of Micronized Fluconazole against Candida albicans and Aspergillus nige

Radhey Srivastava

C. albicans and Aspergillus fumigatus are the two most frequent fungi that cause severe, undetectable infections in impaired persons. Fluconazole is a highly bioavailable antifungal medication of the triazole class. This study uses Aspergillus fumigatus and Candida albicans to examine the biological effects of fluconazole in both its natural form and as a micronized powder. Using the Microniser, an antifungal active medicinal component was reduced to its tiniest feasible particle size. The antifungal effectiveness of the product was contrasted between the plain material (heavy molecules, 200 microns in diameter), and smaller molecules, 2.72 microns in diameter. Antifungal drugs work best when the particles are the tiniest. The properties and particle size of the micronized material (extremely fine powder) are studied by SEM, Fourier transform infrared spectroscopy (FT-IR), and laser diffraction. The antifungal activity of micronized fluconazole is more effective than that of fluconazole plain material (coarser type particles).